Key clinical point: Whole blood DNA methylation patterns measured before the onset of musculoskeletal symptoms can help distinguish patients with psoriasis who will develop psoriatic arthritis (PsA) from those who will not.
Major finding: The model based on 36 highly relevant methylation markers across 15 genes and intergenic regions (false discovery rate-adjusted P < .05; minimum change in methylation of 0.05) could identify patients with psoriasis who developed PsA from those who did not with an area under the receiver operating characteristic curve of 0.964.
Study details: Findings are from a nested case-control study including patients with psoriasis who later developed PsA (n = 58) matched with patients who did not develop PsA (n = 59).
Disclosures: This study was partly supported by an Early Career Research Grant awarded to RA Pollock from the National Psoriasis Foundation. The authors declared no conflicts of interest.
Source: Cruz-Correa OF et al. Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles. Arthritis Rheumatol. 2023 (Jul 18). doi: 10.1002/art.42654